KRAS mutations, which are well-established predictive biomarkers of resistance to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in CRC [36], are known to play a role in mucinous cancers of various sites, including the appendix [37,38,39]. The gene discussed is KRAS; the disease is colorectal carcinoma.